The SMN1 (Survival Motor Neuron 1) gene is crucial for producing the full-length SMN protein, which is essential for the survival of motor neurons. In contrast, the SMN2 gene, a nearly identical copy, typically produces only about 10% of functional SMN protein due to a splicing defect that leads to the exclusion of exon 7 in most transcripts. This difference is significant in the context of Spinal Muscular Atrophy (SMA), a genetic disorder characterized by the loss of motor neurons and muscle atrophy due to insufficient SMN protein levels.
Risdiplam (Evrysdi) is an oral medication that acts as a splicing modifier, enhancing the inclusion of exon 7 in SMN2 transcripts. This results in increased production of functional SMN protein from the SMN2 gene, thereby compensating for the loss of SMN1 function in SMA patients. Risdiplam has been shown to significantly improve SMN protein levels and motor function in clinical trials, making it a vital therapeutic option for individuals with SMA.
In summary, the primary difference between the SMN1 and SMN2 genes lies in their ability to produce functional SMN protein, with SMN1 being the full-length source and SMN2 primarily producing truncated forms. Risdiplam enhances the expression of SMN2, providing a therapeutic avenue for SMA patients who lack sufficient SMN1 protein.
import pandas as pd import matplotlib.pyplot as plt def analyze_smn_expression(data): smn1_data = data[data['gene'] == 'SMN1'] smn2_data = data[data['gene'] == 'SMN2'] plt.figure(figsize=(10, 6)) plt.bar(smn1_data['condition'], smn1_data['expression'], label='SMN1', alpha=0.7) plt.bar(smn2_data['condition'], smn2_data['expression'], label='SMN2', alpha=0.7) plt.xlabel('Condition') plt.ylabel('Expression Level') plt.title('Comparison of SMN1 and SMN2 Expression Levels') plt.legend() plt.show()